Oragenics (NYSEAMERICAN:OGEN) Trading Down 0.3% – Here’s Why

Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN) fell 0.3% during mid-day trading on Tuesday . The company traded as low as $0.7839 and last traded at $0.8295. 74,417 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 421,599 shares. The stock had previously closed at $0.8317.

Oragenics Price Performance

The firm has a market capitalization of $3.54 million, a PE ratio of -0.07 and a beta of 1.09. The company has a 50-day moving average price of $0.80 and a 200 day moving average price of $1.01.

Institutional Investors Weigh In On Oragenics

Several large investors have recently bought and sold shares of OGEN. XTX Topco Ltd bought a new position in Oragenics during the fourth quarter valued at $26,000. Bank of America Corp DE raised its position in shares of Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after buying an additional 15,338 shares in the last quarter. Sabby Management LLC bought a new position in shares of Oragenics in the 3rd quarter valued at about $77,000. DRW Securities LLC lifted its holdings in shares of Oragenics by 82.4% in the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after acquiring an additional 50,900 shares during the last quarter. Finally, Clear Street LLC purchased a new position in Oragenics in the second quarter worth about $270,000. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.